ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Rigel Pharmaceuticals, Inc. ã¯ãè¡æ¶²çŸæ£ããããããã³åžå°å
ç«çŸæ£ãæ²»çããããã®äœååå»è¬åã®çºèŠãšéçºãè¡ã£ãŠããŸããå瀟ã¯ãæ
¢æ§å
ç«è¡å°æ¿æžå°çã®æäººæ£è
ã®æ²»çãç®çãšããçµå£èŸèããã·ã³ãããŒãŒé»å®³å€ Tavalisse ãæäŸããŠããŸãããŸããæž©åŒèªå·±å
ç«æ§æº¶è¡æ§è²§è¡ã®æ²»çãç®çãšãã第 III çžèšåºè©Šéšãå
¥é¢äžã® COVID-19 æ£è
ã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšãããã³ COVID-19 ã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšãè¡ãããŠãã Fostamatinib ãéçºããŠããŸããããã«ãå瀟ã¯ãèªå·±å
ç«ãççãããã³è¡æ¶²è
«çåŠçŸæ£ã察象ãšãã第 I çžèšåºè©Šéšãè¡ãããŠããçµå£ã€ã³ã¿ãŒãã€ãã³å容äœé¢é£ãããŒãŒ 1/4 é»å®³å€ R835ãããã³èªå·±å
ç«ããã³ççæ§çŸæ£ã察象ãšãã第 I çžèšåºè©Šéšãå®äºããå容äœçžäºäœçšã»ãªã³/ã¹ã¬ãªãã³ã¿ã³ãã¯è³ªãããŒãŒ 1 é»å®³å€ R552 ãéçºããŠããŸããå瀟ã¯ãååœ¢è±æ¯çããã®ä»ã®ç®èçŸæ£ã®æ²»çãç®çãšããã€ãã¹ãããŒãŒïŒJAKïŒé»å®³å€ã®éçºããã³åååã«ã€ããŠAclaris Therapeutics International Limited瀟ãåžå
¥JAKé»å®³å€R256ã®éçºããã³åååã«ã€ããŠAstraZeneca AB瀟ãè
«çåŠã«ãããAXLé»å®³å€ã®éçºããã³åååã«ã€ããŠBerGenBio AS瀟ãåºåœ¢ããã³è¡æ¶²æªæ§è
«ççšã®ããŠã¹ããã«ãããã2é»å®³å€ã®éçºã«ã€ããŠç¬¬äžäžå
±ç€Ÿãšç ç©¶ããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠããã»ããããã»ã€è¬åå·¥æ¥æ ªåŒäŒç€Ÿãšãã©ã¹ã¿ããããã®éçºããã³åååã«é¢ããã©ã€ã»ã³ã¹ããã³äŸçµŠå¥çŽãç· çµããŠãããå瀟ã¯ãŸããèªå·±å
ç«çŸæ£ãççæ§çŸæ£ããã®ä»ã®éäžæ¢ç¥çµç³»ïŒéCNSïŒçŸæ£éçºåè£ãå«ãããŸããŸãªé©å¿çã察象ã«R552ãå
±åéçºããã³åååããããã®ã©ã€ã»ã³ã¹å¥çŽããã³æŠç¥çææºãã€ãŒã©ã€ãªãªãŒã»ã¢ã³ãã»ã«ã³ãããŒãšç· çµããŠããã Rigel Pharmaceuticals, Inc. 㯠1996 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµãŠã¹ãµã³ãã©ã³ã·ã¹ã³ã«æ¬ç€Ÿã眮ããŠããŸãã